Abstracts tagged "IL-23"

Abstract Number: 2809 • 2015 ACR/ARHP Annual Meeting
Increased Frequencies of IL-23R Positive T Cells and IL-22 and IL-17 Producing MAIT Cells in the Peripheral Blood of Patients with Ankylosing Spondylitis: Preliminary Results.
Eric Toussirot¹, Caroline Laheurte², Béatrice Gaugler³ and Philippe Saas⁴, ¹Service de Rhumatologie, CHU J Minjoz, Besancon, France, ²Etablissement Français du Sang/ Université de Franche Comté / CBT506 / CHRU, INSERM UMR1098 / Plateforme Biomonitoring, Besançon, France, ³EFS Bourgogne Franche Comté, INSERM UMR1098 / Etablissement Français du Sang / Université de Franche Comté, Besançon, France, ⁴Etablisement Français du Sang ; Université de Franche Comté, INSERM UMR1098, Besançon, France
Background/Purpose: Ankylosing spondylitis (AS) is the prototypic and most common form of spondyloarthritis (SpA). It was recently suggested that IL-23 could play a pivotal role…
Abstract Number: 2819 • 2015 ACR/ARHP Annual Meeting
Rorc Antagonism Inhibits IL-23-Dependent Aberrant Bone Formation in Vivo
Mark Panzenbeck¹, Kathleen Hoyt¹, Donald Souza², Gregg Davis¹, Elizabeth Glynn¹, Thomas Wieckowski¹, Michael Turner¹, Robert Hughes¹, Dustin Smith¹, Christian Harcken¹, Gerald Nabozny³ and Mark Labadia⁴, ¹Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT, ²Immunology & Inflammation, Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT, ³Immunology and Inflammation, Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT, ⁴Immunology, Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT
Background/Purpose: RORγt is a nuclear hormone receptor expressed in Th17 cells and distinct subsets of lymphoid cells, including innate lymphoid cells (ILC), and γδ T-cells.…
Abstract Number: 2822 • 2015 ACR/ARHP Annual Meeting
Increased Peripheral Blood CCR6+/IL-23R+ Gamma Delta T Cells Are Associated with High Disease Activity in Patients with Axial Spondyloarthritis
Elizabeth Mainolfi¹, Susan M. Goodman², Shawn Anderson³, Jon Hill⁴, Thakker Paresh⁵, Meera Ramanujam⁶, Rivka Friedlander⁷, Elli Kim⁷, Dalit Ashany⁸, Ed Purdue⁹, Christine Averill⁹, Michael Nevid⁹, Allison Shaber⁹, Lisa Mandl¹⁰, Steven R. Goldring¹¹, Gerald Nabozny¹ and VP Bykerk², ¹Immunology and Inflammation, Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT, ²Rheumatology, Hospital for Special Surgery, New York, NY, ³Immunology, Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT, ⁴Scientific Knowledge Discovery, Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT, ⁵Transl. Medicine & Clin. Pharmacology, Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT, ⁶Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT, ⁷Department of Medicine, Rheumatology Division, Hospital for Special Surgery, New York, NY, ⁸Rheumatic Disease, Hospital for Special Surgery, New York, NY, ⁹Osteolysis Research Laboratory, Hospital for Special Surgery, New York, NY, ¹⁰Department of Rheumatology, Hospital for Special Surgery, New York, NY, ¹¹Hospital for Special Surgery, New York, NY
Background/Purpose: The IL-23 axis and Th17 type immunity has been implicated in the pathogenesis of Ankylosing Spondylitis (AS) and an enrichment of gamma delta (gd)…
Abstract Number: 1973 • 2014 ACR/ARHP Annual Meeting
Ectopic Lymphoid Neogenesis Is Strongly Associated with Activation of the IL-23/IL-17 Pathway in Rheumatoid Synovitis
Nataliya Yeremenko¹, Raquel Celis², Leonie M. van Duivenvoorde³, Julio Ramirez⁴, Iris C. Blijdorp⁵, Sara Marsal⁶, Jose L. Pablos⁷, Raimon Sanmarti⁴, Juan D. Cañete⁴ and Dominique L. Baeten¹, ¹Department of Clinical Immunology and Rheumatology and Department of Experimental Immunology, Academic Medical Centre/University of Amsterdam, Amsterdam, Netherlands, ²Arthritis Unit, Rheumatology Department, Arthritis Unit, Rheumatology Dpt, Hospital Clinic of Barcelona and IDIBAPS, Barcelona, Spain, ³Experimental Immunology, Department of Clinical Immunology and Rheumatology and Department of Experimental Immunology, Academic Medical Centre/University of Amsterdam, Amsterdam, Netherlands, ⁴Arthritis Unit. Rheumatology Department, Hospital Clínic of Barcelona, Barcelona, Spain, ⁵Department of Clinical Immunology & Rheumatology, Department of Clinical Immunology and Rheumatology and Department of Experimental Immunology, Academic Medical Centre/University of Amsterdam, Amsterdam, Netherlands, ⁶Rheumatology Research Group, Vall d'Hebron Hospital Research Institute, Barcelona, Spain, ⁷Servicio de Reumatología, Instituto de Investigación Hospital 12 de Octubre (I+12), Madrid, Spain
Background/Purpose : The functional relevance of synovial ectopic lymphoid neogenesis (ELN) in rheumatoid arthritis (RA) remains unknown. As ELN correlates with the degree of tissue…
Abstract Number: 806 • 2014 ACR/ARHP Annual Meeting
Association of a Single Nucleotide Polymorphism (SNP) in IL-12B Region with Clinical Features and Peripheral T Cell Profiles of Patients with Takayasu Arteritis
Toshiki Nakajima¹, Hajime Yoshifuji¹, Chikashi Terao², Koji Kitagori¹, Ran Nakashima¹, Yoshitaka Imura³, Naoichiro Yukawa¹, Koichiro Ohmura¹, Takao Fujii¹ and Tsuneyo Mimori¹, ¹Department of Rheumatology and Clinical Immunology, Kyoto University Graduate School of Medicine, Kyoto, Japan, ²Center for Genomic Medicine, Kyoto University, Kyoto, Japan, ³Rheumatology and Clinical Immunology, Kyoto University Graduate School of Medicine, Kyoto, Japan
Background/Purpose We preliminarily found a SNP (A vs. C, rs6871626)　in IL-12B region　as a susceptibility gene to Takayasu arteritis (TAK) by genome-wide association study. IL-12Bencodes IL-12/IL-23…
Abstract Number: 632 • 2014 ACR/ARHP Annual Meeting
IL-23 Mediates Psoriasis-like Inflammation in the SKG Mouse Model of Spondyloarthropathy
Helen Benham¹, Linda Rehaume¹, Athan Baillet¹, Zaied Bhuyan¹, Jaclyn Bowman¹, Dimeng Pang¹, Kristine Kikly², Geoffrey Strutton³, Matthew Brown¹ and Ranjeny Thomas¹, ¹University of Queensland Diamantina Institute, Brisbane, Australia, ²Biotechnology Discovery Research, Eli Lilly and Co, Indianapolis, IN, ³Department of Pathology, Princess Alexandra Hospital, Brisbane, Australia
Background/Purpose Psoriasis (Ps) is a common immune-mediated inflammatory skin disease and is a well- recognised extra-articular manifestation of the spondyloathopathies (SpA). Genetic studies implicate IL-23…
Abstract Number: 2409 • 2013 ACR/ARHP Annual Meeting
Association Of High Serum Interleukin-23 Levels With Porphyromonas Gingivalis Antibodies In Patients With Early Rheumatoid Arthritis
Sheila L. Arvikar¹, Klemen Strle², Deborah S. Collier³, Mark C. Fisher¹, Toshihisa Kawai⁴, Jose U. Scher⁵ and Allen C. Steere⁶, ¹Rheumatology, Allergy & Immunology, Massachusetts General Hospital, Boston, MA, ²Massachusetts General Hospital, Boston, MA, ³Rheumatology, Massachusetts General Hospital, Boston, MA, ⁴Forsyth Institute, Cambridge, MA, ⁵Department of Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY, ⁶Medicine, Center for Immunolgy and Inflammatory Diseases, Massachusetts General Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Rheumatoid arthritis (RA) is associated with an increased frequency of periodontal disease (PD) and antibodies to P. gingivalis (Pg), a major periodontal pathogen. Both…
Abstract Number: 1650 • 2013 ACR/ARHP Annual Meeting
The Route Of T Cell Priming Determines The Requirement For IL-23 In The Development Of Arthritis
Alison Finnegan¹, Yanxia Cao¹ and Susan Olalekan², ¹Dept of Medicine, Rush University Medical Center, Chicago, IL, ²Immunology, Rush University Medical Center, Chicago, IL
Background/Purpose: Rheumatoid arthritis is a very heterogeneous disease and distinct molecular mechanisms may underlie the disease process. IL-23 is an important cytokine for the expansion…
Abstract Number: 717 • 2013 ACR/ARHP Annual Meeting
Patients With Rheumatoid Arthritis Have Impaired Candida Albicans Specific Th17 Responses But Preserved Oral Candida Albicans Protective Immunity
Shrinivas Bishu¹, E. Wern Su², Erich Wikerson³, Donald M. Jones⁴, Kelly A. Reckley⁵, Sarah L. Gaffen³ and Marc C. Levesque⁶, ¹Department of Medicine, Division of Gastroenterology, Hepatology and Nutrition, University of Pittsburgh, Pittsburgh, PA, ²Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ³Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ⁴Rheumatology & Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ⁵Department of Medicine, Division of Rheumatology and Clinical Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA, ⁶Division of Rheumatology and Clinical Immunology, University of Pittsburgh Department of Medicine, Pittsburgh, PA
Background/Purpose: Rheumatoid arthritis (RA) patients are susceptible to infections, even after controlling for the effects of medications. Recent data suggest an important role for the…
Abstract Number: 530 • 2013 ACR/ARHP Annual Meeting
Pattern Recognition Receptor Stimulated Cytokine Expression By Spondyloarthritis Patient Macrophages
Yi-Ping Liu¹, Ashley Bomkamp², Jens Eickhoff³, Jack Schneck², Mike Khan⁴ and Judith Smith⁵, ¹Department of Pediatrics, University of Wisconsin-Madison, Madison, WI, ²University of Wisconsin-Madison, Madison, WI, ³Biostatistics and Medical Informatics, University of Wisconsin-Madison, Madison, WI, ⁴Cellular and Molecular Pathology, University of Wisconsin-Madison, Madison, WI, ⁵Pediatrics, University of Wisconsin-Madison, Madison, WI
Background/Purpose: Spondyloarthritis (SpA) encompasses a group of chronic inflammatory conditions involving axial arthritis that includes ankylosing spondylitis (AS). GWAS studies in AS have implicated multiple…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.